About Gloucester Pharmaceuticals
Gloucester Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2002, and was acquired by Celgene in December 2009. Drugs for cancer treatment are developed by the company. Gloucester Pharmaceuticals has raised $33 million across 5 funding rounds from investors including Celgene, Apple Tree Partners and ProQuest Investments. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Gloucester Pharmaceuticals Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Gloucester Pharmaceuticals was founded in 2002 and is based in Cambridge, United States. Operations focus on oncology pharmaceuticals, with romidepsin identified as a key compound in late-stage development for hematological malignancies. Worldwide exclusive rights to romidepsin, classified as a histone deacetylase (HDAC) inhibitor targeting Class I, II, and IV enzymes, are retained by the company. Preclinical data indicate its potential across various cancer types.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website gloucesterpharma.com
- Social LinkedIn
- Acquired by Celgene (Dec 2009)
- Legal Name Gloucester Pharmaceuticals Inc
Funding Insights of Gloucester Pharmaceuticals
Gloucester Pharmaceuticals has successfully raised a total of $33M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $29 million completed in August 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33M
- Total Rounds 5
- Last Round Series D — $29M
- First Round $1.5M
(Mar 2009)
- Investors Count 5
All 5 funding rounds of Gloucester Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2009 | $29M | Series D | – | Novo Holdings | |
| Aug 2009 | $500,000 | Seed | – | – | – |
| Jul 2009 | $500,000 | Seed | – | – | – |
| Jun 2009 | $1.5M | Seed | – | – | – |
| Mar 2009 | $1.5M | Seed | – | – | – |
6 investors in total: 6 institutional.
Investors in Gloucester Pharmaceuticals
Gloucester Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Celgene, Apple Tree Partners and ProQuest Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Apple Tree Partners is engaged in life sciences venture capital. | appletreepartners.com | |||
| proquestvc.com | ||||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Gloucester Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Gloucester Pharmaceuticals
4 dated milestones of Gloucester Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Gloucester Pharmaceuticals is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series D, of $29.0M.
- Exit Acquired by Celgene.
Competitors of Gloucester Pharmaceuticals
Gloucester Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Gloucester Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Gloucester Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gloucester Pharmaceuticals
Complete news archive for Gloucester Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gloucester Pharmaceuticals
Gloucester Pharmaceuticals was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Gloucester Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Gloucester Pharmaceuticals is a funded company, having raised a total of $33M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Mar 2009.
Gloucester Pharmaceuticals was founded in 2002 and is based in Cambridge, United States. Operations focus on oncology pharmaceuticals, with romidepsin identified as a key compound in late-stage development for hematological malignancies. Worldwide exclusive rights to romidepsin, classified as a histone deacetylase (HDAC) inhibitor targeting Class I, II, and IV enzymes, are retained by the company. Preclinical data indicate its potential across various cancer types.
Gloucester Pharmaceuticals has 6 investors. Key investors include Celgene, Apple Tree Partners, ProQuest Investments, Prospect Venture Partners, and Rho Capital Partners.
Gloucester Pharmaceuticals operates through Gloucester Pharmaceuticals Inc.
Yes. Gloucester Pharmaceuticals was acquired by Celgene in December 2009.